Global Sepsis Diagnostics Market (2021 to 2026) - Evolution of Novel Biomarkers for Sepsis Diagnosis Presents Opportunities - ResearchAndMarkets.com

The "Global Sepsis Diagnostics Market by Technology (Microbiology, PCR, Sequencing, Biomarkers), Product (Reagents, Assay, Instruments, Software), Test Type (Lab, POC), Pathogen (Bacterial, Viral, Fungal), End User (Hospital, Pathology Lab) - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The global sepsis diagnostics market size is expected to reach USD 771 million by 2026 from USD 503 million in 2021, at a CAGR of 8.9%.

The demand is expected to grow due to the rising incidence of sepsis, a growing number of surgical procedures, high incidence of hospital-acquired infections, and increasing availability of a wide variety of sepsis diagnostic devices. The sepsis diagnostics industry is segmented on the technology, product, method, pathogen, test type, end-user, and region.

The blood culture segment accounted for the largest share of the sepsis diagnostics industry, by end-user, in 2021

Based on end-users, the sepsis diagnostics market is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. The blood culture accounted for the largest share of the market due to the increasing incidences of sepsis coupled with the growing adoption of blood culture techniques for the diagnosis of sepsis.

The blood culture media segment accounted for the largest share of the sepsis diagnostics market, by product, in 2021

The market, by product, is segmented into blood culture media, assays & reagents, instruments, and software. The blood culture media segment accounted for the largest share of the sepsis diagnostics industry due to the usage of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis across the globe.

North America accounted for the largest share of the sepsis diagnostics market

North America accounted for the largest share of the global market, followed by Europe. This can primarily be attributed to the extensive availability of advanced sepsis diagnostic technologies, well-established distribution channels, and significant public awareness about the clinical benefits of diagnostic products in risk assessment for infectious diseases.

Market Dynamics

Drivers

• High Incidence of Sepsis
• Rising Incidence of Hospital-Acquired Infections
• Growing Funding for Sepsis-Related Research

Restraints

• High Cost of Automated Diagnostic Devices

Opportunities

• Development of Rapid Diagnostic/Poc Techniques for Early Sepsis Diagnosis
• Evolution of Novel Biomarkers for Sepsis Diagnosis
• Growth Opportunities in Emerging Economies

Challenges

• Lack of Awareness and Limited Protocols for Sepsis Diagnosis
• Shortage of Skilled Healthcare Professionals

Companies Mentioned

• Abbott Laboratories
• Advandx
• Alifax S.R.L.
• Axis-Shield Diagnostics
• Becton, Dickinson, and Company
• Biomerieux
• Boditech Med Inc.
• Bruker Corporation
• Danaher Corporation
• Ekf Diagnostics
• F. Hoffmann-La Roche Ag
• Immunexpress Inc.
• Luminex
• Quidel Corporation
• Response Biomedical Corp.
• Seegene, Inc.
• Siemens Healthineers
• Sysmex Corporation
• T2 Biosystems
• Thermo Fisher Scientific

For more information about this report visit https://www.researchandmarkets.com/r/pko365.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220322005904/en/